All news

Vaccine increases treatment responsiveness of pancreatic cancer

Added: Wednesday 25 June 2014

Recent research finds that pancreatic ductal adenocarcinomas (PDAC), which do not normally respond to immunotherapy, may respond when "primed" with a therapeutic vaccine. Researchers treated PDAC patients with a therapeutic vaccine and a low dose of a chemotherapy drug before surgery. This caused immune cells inside the tumours to express proteins that may make them responsive to immunotherapy. This news, published in Cancer Immunology Research, suggests a new model for treating typically nonimmunogenic cancers.